Drug and Medication Industry: Istituto Clinico Humanitas – Developmental Therapeutics Review – Q4 2010

• Publication date: December 2010

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by G...

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Istituto Clinico Humanitas - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Istituto Clinico Humanitas human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Istituto Clinico Humanitas with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Istituto Clinico Humanitas’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Istituto Clinico Humanitas’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Istituto Clinico Humanitas in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Istituto Clinico Humanitas’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Istituto Clinico Humanitas.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Istituto Clinico Humanitas and identify potential opportunities in those areas.

Global Therapy Industry

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Istituto Clinico Humanitas Snapshot 5
Istituto Clinico Humanitas Overview 5
Key Information 5
Key Facts 5
Istituto Clinico Humanitas – Research and Development Overview 6
Key Therapeutic Areas 6
Istituto Clinico Humanitas – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
Istituto Clinico Humanitas – Pipeline Products Glance 12
Istituto Clinico Humanitas Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 14
Istituto Clinico Humanitas – Drug Profiles 15
BAY-43-9006 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Bortezomib + IGEV 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Carboplatin + Alimta 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Doxorubicin + Ifosfamide 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gemcitabine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Lenalidomide + Dexamethasone 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Oral Vorinostat + Topotecan 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Pegfilgrastim 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Revlimid + Dexamethasone 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Suberoylanilide Hydroxamic Acid + Topotecan 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Sunitinib 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
TLC D-99 + ifosfamide 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Trastuzumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Lapatinib + Sorafenib 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Istituto Clinico Humanitas – Pipeline Analysis 32
Istituto Clinico Humanitas – Pipeline Products by Therapeutic Class 32
Istituto Clinico Humanitas Pipeline Products By Target 34
Istituto Clinico Humanitas – Pipeline Products by Route of Administration 36
Istituto Clinico Humanitas – Pipeline Products by Molecule Type 37
Istituto Clinico Humanitas – Locations And Subsidiaries 38
Head Office 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 40
Contact Us 40
Disclaimer 40List of Tables
Istituto Clinico Humanitas – Pipeline by Therapy Area and Indication, 2010 7
Istituto Clinico Humanitas – Pipeline by Stage of Development, 2010 9
Istituto Clinico Humanitas – Monotherapy Products in Pipeline, 2010 10
Istituto Clinico Humanitas – Combination Treatment Modalities in Pipeline, 2010 11
Istituto Clinico Humanitas - Phase II, 2010 12
Istituto Clinico Humanitas - Phase I, 2010 14
Istituto Clinico Humanitas - Pipeline By Therapeutic Class, 2010 32
Istituto Clinico Humanitas - Pipeline By Target, 2010 34
Istituto Clinico Humanitas – Pipeline By Route of Administration, 2010 36
Istituto Clinico Humanitas – Pipeline By Molecule Type, 2010 37

List of Figures
Istituto Clinico Humanitas – Pipeline by Therapy Area and Indication, 2010 7
Istituto Clinico Humanitas – Pipeline by Stage of Development, 2010 9
Istituto Clinico Humanitas – Monotherapy Products in Pipeline, 2010 10
Istituto Clinico Humanitas – Combination Treatment Modalities in Pipeline, 2010 11
Istituto Clinico Humanitas – Pipeline By Therapeutic Class, 2010 32
Istituto Clinico Humanitas - Pipeline By Target, 2010 34
Istituto Clinico Humanitas – Pipeline By Route of Administration, 2010 36